Atlas Trials

Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients

Clinical trial NCT02511184 · TERMINATED

Trial details

NCT number
NCT02511184
Sponsor
Pfizer
Status
TERMINATED
Phase
Phase 1
Study type
INTERVENTIONAL
ALK-positive Advanced NSCLC
Start date
2015-10-01
Primary completion
2017-12-01
Enrollment
9

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.